Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Pharming maart 2018

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,695   -0,007   (-0,93%) Dagrange 0,683 - 0,700 5.038.620   Gem. (3M) 4,8M

Pharming maart 2018

Volgen
20.968 Posts
Pagina: «« 1 ... 610 611 612 613 614 ... 1049 »» | Laatste | Omlaag ↓
  1. HobbyBeurs 13 maart 2018 18:52
    quote:

    voda schreef op 13 maart 2018 17:41:

    09 jun 0,317 10 jul 0,440 08 aug 0,423 06 sep 0,451 05 okt 0,740 03 nov 1,108
    12 jun 0,325 11 jul 0,441 09 aug 0,417 07 sep 0,456 06 okt 0,742 06 nov 1,280
    13 jun 0,329 12 jul 0,440 10 aug 0,421 08 sep 0,450 09 okt 0,760 07 nov 1,251
    14 jun 0,325 13 jul 0,458 11 aug 0,406 11 sep 0,485 10 okt 0,785 08 nov 1,344
    15 jun 0,321 14 jul 0,479 14 aug 0,410 12 sep 0,470 11 okt 0,800 09 nov 1,239
    16 jun 0,321 17 jul 0,476 15 aug 0,423 13 sep 0,474 12 okt 0,814 10 nov 1,291
    19 jun 0,324 18 jul 0,452 16 aug 0,425 14 sep 0,473 13 okt 0,816 13 nov 1,318
    20 jun 0,327 19 jul 0,459 17 aug 0,430 15 sep 0,493 16 okt 0,815 14 nov 1,287
    21 jun 0,327 20 jul 0,455 18 aug 0,439 18 sep 0,555 17 okt 0,770 15 nov 1,230
    22 jun 0,323 21 jul 0,456 21 aug 0,464 19 sep 0,566 18 okt 0,722 16 nov 1,262
    23 jun 0,323 24 jul 0,453 22 aug 0,468 20 sep 0,563 19 okt 0,656 17 nov 1,288
    26 jun 0,337 25 jul 0,473 23 aug 0,461 21 sep 0,586 20 okt 0,710 20 nov 1,305
    27 jun 0,335 26 jul 0,489 24 aug 0,459 22 sep 0,634 23 okt 0,732 21 nov 1,303
    28 jun 0,331 27 jul 0,461 25 aug 0,450 25 sep 0,692 24 okt 0,699 22 nov 1,296
    29 jun 0,330 28 jul 0,451 28 aug 0,444 26 sep 0,663 25 okt 0,750 23 nov 1,264
    30 jun 0,333 31 jul 0,440 29 aug 0,426 27 sep 0,697 26 okt 0,810 24 nov 1,279
    03 jul 0,331 01 aug 0,417 30 aug 0,456 28 sep 0,695 27 okt 0,795 27 nov 1,290
    04 jul 0,333 02 aug 0,424 31 aug 0,458 29 sep 0,704 30 okt 0,850 28 nov 1,272
    05 jul 0,344 03 aug 0,438 01 sep 0,456 02 okt 0,748 31 okt 0,983 29 nov 1,255
    06 jul 0,360 04 aug 0,431 04 sep 0,451 03 okt 0,735 01 nov 1,007 30 nov 1,243
    07 jul 0,387 07 aug 0,422 05 sep 0,451 04 okt 0,741 02 nov 1,038 01 dec 1,270

    04 dec 1,231 02 jan 1,221 26 jan 1.541 21 feb 1.358
    05 dec 1,208 03 jan 1.271 29 jan 1,563 22 feb 1.360
    06 dec 1,188 04 jan 1.217 30 jan 1,559 23 feb 1.299
    07 dec 1,251 05 jan 1.249 31 jan 1,544 26 feb 1.356
    08 dec 1,220 08 jan 1.254 01 feb 1.513 27 feb 1.360
    11 dec 1.239 09 jan 1.255 02 feb 1.465 28 feb 1.372
    12 dec 1.231 10 jan 1.233 05 feb 1.371 01 mrt 1.319
    13 dec 1.206 11 jan 1.283 06 feb 1.276 02 mrt 1.340
    14 dec 1.200 12 jan 1.290 07 feb 1.525 05 mrt 1.490!!
    15 dec 1.167 15 jan 1.270 08 feb 1.469 06 mrt 1.420
    18 dec 1.074 16 jan 1.291 09 feb 1.405 07 mrt 1.291!! jaarcijfers
    19 dec 1.151 17 jan 1.302 12 feb 1.485 08 mrt 1.270
    20 dec 1.121 18 jan 1.313 13 feb 1.464 09 mrt 1.180 !
    21 dec 1.100 19 jan 1.500 14 feb 1.462 12 mrt 1.191
    22 dec 1.136 22 jan 1.545 15 feb 1.471 13 mrt 1.194
    27 dec 1.125 23 jan 1.500 16 feb 1.458
    28 dec 1.134 24 jan 1.537 19 feb 1.362
    29 dec 1.132 25 jan 1.522 20 feb 1.390
    Dank voda voor de update
  4. [verwijderd] 13 maart 2018 19:15
    quote:

    lucas D schreef op 13 maart 2018 18:52:

    31 jan 1,544
    28 feb 1.372
    01 mrt 1.319
    02 mrt 1.340
    05 mrt 1,490
    06 mrt 1,420
    07 mrt 1,291
    08 mrt 1,270
    09 mrt 1,180
    12 mrt 1,191
    13 mrt 1,194 Peter 58, winnaar

    Bedankt weer Hans, vandaag begon de beursdag niet zoals je als aandeelhouder graag ziet, het waarom van zo'n koersdaling direct na de opening is onverklaarbaar zonder slecht nieuws, dat was er niet en er was dan ook niets om hier in mee te gaan. Opvallend is het wel dat veel beleggers op dit forum echt bij de dag leven en in die context ook reageren. Zou willen zeggen, vergroot je zichtveld zodat je altijd kunt nadenken over wat je nu echt wil.
    Een slotkoers van 1,194 is hoewel miniem toch de 2e dag dat de koers hoger eindigt dan de voorgaande dag. Ik ben er blij mee, net als dat ik erg blij ben dat er ook weer wat forumleden die zich al even niet lieten zien er weer waren.

    Morgen weer een nieuwe dag met nieuwe kansen, en ik hoop op een stijging van de koers vanaf moment van opening beurs tot sluiting beurs, daar zijn wel weer een keer aan toe.
    En natuurlijk,

    Morgen weer een dag, met nieuwe kansen! :-)
  6. forum rang 6 de schaatser 13 maart 2018 19:44
    Ik ga mij niet meer wagen aan koersprognoses.Zat er helemaal naast. Pharming is een geweldig groeiaandeel en ik snap dan ook helemaal niets van de lage koers waar zij zich nu bevindt. Onder de farmacie aandelen zijn zij als 1 van de weinigen die in 2018 echte winst gaan maken. Daarna wordt alles alleen maar beter.In de pijplijn zitten ook goede kansen. Als je al met al vergelijkt met Kiadis, Galapagos maar ook bijvoorbeeld Alfen die wordt geïntroduceerd met een K/W van 170. Ik weet het, ik weet het je mag geen appels met peren vergelijken. Maar we zitten hier allemaal om het hoogste rendement te halen, waarom zal je dan in de andere 3 voorbeelden investeren. Voor mij is Pharming een groei aandeel.
  9. CBM 13 maart 2018 19:52
    Wellington Shields Capital Management Raised By $975,000 Its Main Street Capital (MAIN) Position; PHARMING GROUP NV LEIDEN ORDINARY SHARES (PHGUF) Shorts Down By 2.86%

    March 13, 2018 - By Hazel Jackson

    PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF) had a decrease of 2.86% in short interest. PHGUF’s SI was 1.51 million shares in March as released by FINRA. Its down 2.86% from 1.55M shares previously. With 13,500 avg volume, 112 days are for PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF)’s short sellers to cover PHGUF’s short positions. The SI to PHARMING GROUP NV LEIDEN ORDINARY SHARES’s float is 0.31%. The stock increased 3.45% or $0.05 during the last trading session, reaching $1.5. About 4,500 shares traded. Pharming Group N.V. (OTCMKTS:PHGUF) has 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

    Wellington Shields Capital Management Llc increased Main Street Capital Corp (MAIN) stake by 72.05% reported in 2017Q3 SEC filing. Wellington Shields Capital Management Llc acquired 25,000 shares as Main Street Capital Corp (MAIN)’s stock rose 2.44%. The Wellington Shields Capital Management Llc holds 59,700 shares with $2.37M value, up from 34,700 last quarter. Main Street Capital Corp now has $2.19 billion valuation. The stock increased 0.78% or $0.29 during the last trading session, reaching $37.3. About 162,472 shares traded. Main Street Capital Corporation (NYSE:MAIN) has risen 23.33% since March 13, 2017 and is uptrending. It has outperformed by 6.63% the S&P500.

    Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for treatment of rare diseases and unmet medical needs. The company has market cap of $825.28 million. The companyÂ’s lead product is Ruconest , a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It currently has negative earnings. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human Factor VIII, a natural human blood clotting factor for treating Haemophilia A.

    Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.28, from 1.33 in 2017Q2. It worsened, as 16 investors sold MAIN shares while 39 reduced holdings. 20 funds opened positions while 53 raised stakes. 14.20 million shares or 7.23% more from 13.24 million shares in 2017Q2 were reported. Atlantic Tru Group Limited Liability holds 62,146 shares or 0.01% of its portfolio. Silver Management Ltd Liability Company owns 3.49% invested in Main Street Capital Corporation (NYSE:MAIN) for 21,810 shares. Carlson Capital reported 0.76% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Northern Trust Corp stated it has 0% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Yorktown Mgmt Rech Company invested in 8,800 shares or 0.09% of the stock. Macquarie Grp Limited invested in 0.08% or 1.11M shares. 314,082 are owned by Blackrock Inc. British Columbia – Canada-based Pacad has invested 0.01% in Main Street Capital Corporation (NYSE:MAIN). Next holds 0.02% of its portfolio in Main Street Capital Corporation (NYSE:MAIN) for 2,100 shares. Cap Investment Ltd Liability Corp holds 0.09% in Main Street Capital Corporation (NYSE:MAIN) or 31,675 shares. Management Professionals, Texas-based fund reported 26,229 shares. Hamilton Point Invest Lc has invested 1.05% in Main Street Capital Corporation (NYSE:MAIN). Private Advisor Limited has invested 0.02% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Cetera Advisor Networks Ltd Liability holds 0.01% or 7,504 shares. Hightower Advsrs accumulated 102,495 shares.

    Among 8 analysts covering Street Capital Group (NYSE:MAIN), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. Street Capital Group had 19 analyst reports since August 7, 2015 according to SRatingsIntel. Citigroup downgraded the shares of MAIN in report on Thursday, May 11 to “Underperform” rating. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, September 22. On Monday, January 9 the stock rating was downgraded by Robert W. Baird to “Neutral”. The stock of Main Street Capital Corporation (NYSE:MAIN) has “Neutral” rating given on Wednesday, April 27 by Janney Capital. As per Thursday, May 11, the company rating was downgraded by Raymond James. RBC Capital Markets maintained the shares of MAIN in report on Sunday, November 5 with “Buy” rating. The stock has “Hold” rating by Raymond James on Tuesday, November 7. The stock has “Outperform” rating by National Bank Canada on Friday, August 7. The firm earned “Outperform” rating on Monday, February 27 by Raymond James. The stock of Main Street Capital Corporation (NYSE:MAIN) has “Neutral” rating given on Monday, February 26 by National Securities.

    -Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
  10. forum rang 6 de schaatser 13 maart 2018 19:53
    quote:

    JacobusJW schreef op 13 maart 2018 16:54:

    [...]

    Het is maar de vraag of de koers zo ver was gedaald en daar ligt nu net het punt. Dat de koers te hoog was is nog maar de vraag en niet te verantwoorden als we er binnenkort weer op staan.

    De markt kan zich heel goed zelf corrigeren. Zouden de aandelen van bedrijven zonder shortpositie alleen maar stijgen?

    Nog niet zo lang geleden werd Besi overduidelijk van €30 naar €12 geshort, nu staan ze op €83.
    Het voorbeeld van Besi sluit mooi aan op mijn stukje eerder op deze pagina.
  12. CBM 13 maart 2018 19:55
    Misschien toch even lezen.
    Wellington Shields Capital Management Raised By $975,000 Its Main Street Capital (MAIN) Position; PHARMING GROUP NV LEIDEN ORDINARY SHARES (PHGUF) Shorts Down By 2.86%

    March 13, 2018 - By Hazel Jackson

    PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF) had a decrease of 2.86% in short interest. PHGUF’s SI was 1.51 million shares in March as released by FINRA. Its down 2.86% from 1.55M shares previously. With 13,500 avg volume, 112 days are for PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF)’s short sellers to cover PHGUF’s short positions. The SI to PHARMING GROUP NV LEIDEN ORDINARY SHARES’s float is 0.31%. The stock increased 3.45% or $0.05 during the last trading session, reaching $1.5. About 4,500 shares traded. Pharming Group N.V. (OTCMKTS:PHGUF) has 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

    Wellington Shields Capital Management Llc increased Main Street Capital Corp (MAIN) stake by 72.05% reported in 2017Q3 SEC filing. Wellington Shields Capital Management Llc acquired 25,000 shares as Main Street Capital Corp (MAIN)’s stock rose 2.44%. The Wellington Shields Capital Management Llc holds 59,700 shares with $2.37M value, up from 34,700 last quarter. Main Street Capital Corp now has $2.19 billion valuation. The stock increased 0.78% or $0.29 during the last trading session, reaching $37.3. About 162,472 shares traded. Main Street Capital Corporation (NYSE:MAIN) has risen 23.33% since March 13, 2017 and is uptrending. It has outperformed by 6.63% the S&P500.

    Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for treatment of rare diseases and unmet medical needs. The company has market cap of $825.28 million. The companyÂ’s lead product is Ruconest , a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It currently has negative earnings. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human Factor VIII, a natural human blood clotting factor for treating Haemophilia A.

    Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.28, from 1.33 in 2017Q2. It worsened, as 16 investors sold MAIN shares while 39 reduced holdings. 20 funds opened positions while 53 raised stakes. 14.20 million shares or 7.23% more from 13.24 million shares in 2017Q2 were reported. Atlantic Tru Group Limited Liability holds 62,146 shares or 0.01% of its portfolio. Silver Management Ltd Liability Company owns 3.49% invested in Main Street Capital Corporation (NYSE:MAIN) for 21,810 shares. Carlson Capital reported 0.76% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Northern Trust Corp stated it has 0% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Yorktown Mgmt Rech Company invested in 8,800 shares or 0.09% of the stock. Macquarie Grp Limited invested in 0.08% or 1.11M shares. 314,082 are owned by Blackrock Inc. British Columbia – Canada-based Pacad has invested 0.01% in Main Street Capital Corporation (NYSE:MAIN). Next holds 0.02% of its portfolio in Main Street Capital Corporation (NYSE:MAIN) for 2,100 shares. Cap Investment Ltd Liability Corp holds 0.09% in Main Street Capital Corporation (NYSE:MAIN) or 31,675 shares. Management Professionals, Texas-based fund reported 26,229 shares. Hamilton Point Invest Lc has invested 1.05% in Main Street Capital Corporation (NYSE:MAIN). Private Advisor Limited has invested 0.02% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Cetera Advisor Networks Ltd Liability holds 0.01% or 7,504 shares. Hightower Advsrs accumulated 102,495 shares.

    Among 8 analysts covering Street Capital Group (NYSE:MAIN), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. Street Capital Group had 19 analyst reports since August 7, 2015 according to SRatingsIntel. Citigroup downgraded the shares of MAIN in report on Thursday, May 11 to “Underperform” rating. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, September 22. On Monday, January 9 the stock rating was downgraded by Robert W. Baird to “Neutral”. The stock of Main Street Capital Corporation (NYSE:MAIN) has “Neutral” rating given on Wednesday, April 27 by Janney Capital. As per Thursday, May 11, the company rating was downgraded by Raymond James. RBC Capital Markets maintained the shares of MAIN in report on Sunday, November 5 with “Buy” rating. The stock has “Hold” rating by Raymond James on Tuesday, November 7. The stock has “Outperform” rating by National Bank Canada on Friday, August 7. The firm earned “Outperform” rating on Monday, February 27 by Raymond James. The stock of Main Street Capital Corporation (NYSE:MAIN) has “Neutral” rating given on Monday, February 26 by National Securities.

    -Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
  14. CBM 13 maart 2018 20:00
    Nieuws van 2 uur oud.
    Ik plaats het nog 1 keer.

    Wellington Shields Capital Management Raised By $975,000 Its Main Street Capital (MAIN) Position; PHARMING GROUP NV LEIDEN ORDINARY SHARES (PHGUF) Shorts Down By 2.86%

    March 13, 2018 - By Hazel Jackson

    PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF) had a decrease of 2.86% in short interest. PHGUF’s SI was 1.51 million shares in March as released by FINRA. Its down 2.86% from 1.55M shares previously. With 13,500 avg volume, 112 days are for PHARMING GROUP NV LEIDEN ORDINARY SHARES (OTCMKTS:PHGUF)’s short sellers to cover PHGUF’s short positions. The SI to PHARMING GROUP NV LEIDEN ORDINARY SHARES’s float is 0.31%. The stock increased 3.45% or $0.05 during the last trading session, reaching $1.5. About 4,500 shares traded. Pharming Group N.V. (OTCMKTS:PHGUF) has 0.00% since March 13, 2017 and is . It has underperformed by 16.70% the S&P500.

    Wellington Shields Capital Management Llc increased Main Street Capital Corp (MAIN) stake by 72.05% reported in 2017Q3 SEC filing. Wellington Shields Capital Management Llc acquired 25,000 shares as Main Street Capital Corp (MAIN)’s stock rose 2.44%. The Wellington Shields Capital Management Llc holds 59,700 shares with $2.37M value, up from 34,700 last quarter. Main Street Capital Corp now has $2.19 billion valuation. The stock increased 0.78% or $0.29 during the last trading session, reaching $37.3. About 162,472 shares traded. Main Street Capital Corporation (NYSE:MAIN) has risen 23.33% since March 13, 2017 and is uptrending. It has outperformed by 6.63% the S&P500.

    Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for treatment of rare diseases and unmet medical needs. The company has market cap of $825.28 million. The companyÂ’s lead product is Ruconest , a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, and South Korea. It currently has negative earnings. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human Factor VIII, a natural human blood clotting factor for treating Haemophilia A.

    Investors sentiment decreased to 1.05 in 2017 Q3. Its down 0.28, from 1.33 in 2017Q2. It worsened, as 16 investors sold MAIN shares while 39 reduced holdings. 20 funds opened positions while 53 raised stakes. 14.20 million shares or 7.23% more from 13.24 million shares in 2017Q2 were reported. Atlantic Tru Group Limited Liability holds 62,146 shares or 0.01% of its portfolio. Silver Management Ltd Liability Company owns 3.49% invested in Main Street Capital Corporation (NYSE:MAIN) for 21,810 shares. Carlson Capital reported 0.76% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Northern Trust Corp stated it has 0% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Yorktown Mgmt Rech Company invested in 8,800 shares or 0.09% of the stock. Macquarie Grp Limited invested in 0.08% or 1.11M shares. 314,082 are owned by Blackrock Inc. British Columbia – Canada-based Pacad has invested 0.01% in Main Street Capital Corporation (NYSE:MAIN). Next holds 0.02% of its portfolio in Main Street Capital Corporation (NYSE:MAIN) for 2,100 shares. Cap Investment Ltd Liability Corp holds 0.09% in Main Street Capital Corporation (NYSE:MAIN) or 31,675 shares. Management Professionals, Texas-based fund reported 26,229 shares. Hamilton Point Invest Lc has invested 1.05% in Main Street Capital Corporation (NYSE:MAIN). Private Advisor Limited has invested 0.02% of its portfolio in Main Street Capital Corporation (NYSE:MAIN). Cetera Advisor Networks Ltd Liability holds 0.01% or 7,504 shares. Hightower Advsrs accumulated 102,495 shares.

    Among 8 analysts covering Street Capital Group (NYSE:MAIN), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. Street Capital Group had 19 analyst reports since August 7, 2015 according to SRatingsIntel. Citigroup downgraded the shares of MAIN in report on Thursday, May 11 to “Underperform” rating. The stock has “Outperform” rating by RBC Capital Markets on Tuesday, September 22. On Monday, January 9 the stock rating was downgraded by Robert W. Baird to “Neutral”. The stock of Main Street Capital Corporation (NYSE:MAIN) has “Neutral” rating given on Wednesday, April 27 by Janney Capital. As per Thursday, May 11, the company rating was downgraded by Raymond James. RBC Capital Markets maintained the shares of MAIN in report on Sunday, November 5 with “Buy” rating. The stock has “Hold” rating by Raymond James on Tuesday, November 7. The stock has “Outperform” rating by National Bank Canada on Friday, August 7. The firm earned “Outperform” rating on Monday, February 27 by Raymond James. The stock of Main Street Capital Corporation (NYSE:MAIN) has “Neutral” rating given on Monday, February 26 by National Securities.

    -Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.
  15. [verwijderd] 13 maart 2018 20:03
    Voor de verandering gisteren eens geen uitbreiding van shortposities in Pharming (tenminste, niet van shorters vanaf 0,5%). Maar goed, minimaal 3% van de aandelen zit daar al. En als er nog een paar kleine zijn, zou dat zo 4 of 5% kunnen zijn. Bij 4% gaat het om ruim 23 miljoen aandelen. Dat daarmee de koers beïnvloed kan worden, behoeft geen betoog en hebben we vermoedelijk al gemerkt. Gelukkig nog geen Fugro waar meer dan 11% is geshort.
  17. forum rang 7 lucas D 13 maart 2018 20:17
    Ik mis 'tKVED, weet dat hij enorm zijn nek heeft uitgestoken, met waar het nu op lijkt te hoge verwachtingen. Lijkt, maar de verwachtingen waren goed!
    Daarom schrijf ik dit:
    Die verwachtingen had ik ook, sterker nog ik heb ze nog steeds. Klinkt mogelijk wat eigenzinnig als je naar de huidige koers kijkt, dan denk je waar heeft hij het nog over?
    Nou dat zal ik even uitleggen, het zijn niet de verwachtingen die te hoog waren, het is de koers die te laag stond (door eerder dan bedoeld was converteren van obligaties) voor de cijfers en na de cijfers nog een behoorlijk stuk omlaag gegaan zijn omdat de omzet van het 4e kwartaal niet aan wat verwacht kon worden voldeed.

    De verwachtingen waren goed.

    Pharming heeft er het 4e kwartaal met de pet naar gegooid, dat zij ondanks dat een concurrent niet kon leveren, niet meer dat 26% omzet meer behaalde dan in het 3e kwartaal, waar nauwelijks sprake was van een niet leverende concurrent. (de Vries zijn eigen woorden)
    Het woord blamage is een te groot woord, maar gezien de omstandigheden zeker ondermaats.

    De verwachtingen waren goed, de koers zou aan de verwachtingen voldaan hebben als Pharming had gedaan wat verwacht mocht worden, dat hebben ze niet gedaan.

    De verwachtingen waren goed, en de verwachtingen zijn goed.
20.968 Posts
Pagina: «« 1 ... 610 611 612 613 614 ... 1049 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Vertrek CEO overschaduwt goede resultaten Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: volop groeimotoren voor Pharming
  2. AEX opent waarschijnlijk hóger op Super Thursday met Besi, Unilever en Pharming
  3. Topman De Vries stopt bij Pharming
  4. Pharming start met Fase II klinische studie leniolisib
  5. Pharming: herstelpotentieel van 100%
  6. Slotcall: BAM en Pharming vinden gretig aftrek op groen gekleurd Damrak
  7. Micron-effect op de beurs? AEX gaat fraaie opening tegemoet, chipaandelen Azië vliegen
  8. Brits groen licht voor Joenja van Pharming
  9. Video: CEO tevreden over ontwikkelingen bij Pharming
  10. Dubbeltje op zijn kant voor AEX, terwijl cijferstorm aantrekt tot windkracht 10